 Myeloid Cell Leukemia Sequence 1 Protein
"Myeloid Cell Leukemia Sequence 1 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
| Descriptor ID |
D064549
|
| MeSH Number(s) |
D12.644.360.075.718.984 D12.776.476.075.718.968 D12.776.624.664.700.169.500
|
| Concept/Terms |
Myeloid Cell Leukemia Sequence 1 Protein- Myeloid Cell Leukemia Sequence 1 Protein
- Myeloid Cell Leukemia Sequence 1
- Myeloid Cell Factor-1
- Cell Factor-1, Myeloid
- Factor-1, Myeloid Cell
- Myeloid Cell Factor 1
- Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1
- Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1
|
Below are MeSH descriptors whose meaning is more general than "Myeloid Cell Leukemia Sequence 1 Protein".
Below are MeSH descriptors whose meaning is more specific than "Myeloid Cell Leukemia Sequence 1 Protein".
This graph shows the total number of publications written about "Myeloid Cell Leukemia Sequence 1 Protein" by people in this website by year, and whether "Myeloid Cell Leukemia Sequence 1 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloid Cell Leukemia Sequence 1 Protein" by people in Profiles.
-
Mukherjee N, Katsnelson E, Brunetti TM, Michel K, Couts KL, Lambert KA, Robinson WA, McCarter MD, Norris DA, Tobin RP, Shellman YG. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis. 2024 Mar 08; 15(3):198.
-
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 06 08; 11(6):443.
-
Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, Diamond JR. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ?-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 11; 18(11):1916-1925.
-
Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. Cancer Res. 2018 10 15; 78(20):5793-5807.
-
Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18; 8(29):46801-46817.
-
Mandell MA, Jain A, Kumar S, Castleman MJ, Anwar T, Eskelinen EL, Johansen T, Prekeris R, Deretic V. TRIM17 contributes to autophagy of midbodies while actively sparing other targets from degradation. J Cell Sci. 2016 10 01; 129(19):3562-3573.
-
Li Z, Younger K, Gartenhaus R, Joseph AM, Hu F, Baer MR, Brown P, Davila E. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest. 2015 Mar 02; 125(3):1081-97.
-
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, S?nchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, G?mez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb; 4(2):232-45.
-
Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MK, Smythe WR, Cao X. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer. 2012 Nov 21; 12:541.
-
Nifoussi SK, Vrana JA, Domina AM, De Biasio A, Gui J, Gregory MA, Hann SR, Craig RW. Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer. PLoS One. 2012; 7(10):e47060.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|